1349697-72-8

Upstream product

• 157197-06-3 1-hydroxy-5-(2'-methylprop-2'-enyloxy)-9,10-anthraquinone 
• 100-39-0 benzyl bromide 
• 117-12-4 1,5-dihydroxyanthraquinone 
• 1349697-71-7 (R)-1,5-bis(benzyloxy)-2-((2-methyl-4-oxooxetan-2-yl)methyl)anthracene-9,10-dione 
• 1349697-68-2 (R)-1,5-bis(benzyloxy)-2-((2-methyloxiran-2-yl)methyl)anthracene-9,10-dione 
• 1349697-70-6 (R)-3-(1,5-bis(benzyloxy)-9,10-dioxo-9,10-dihydroanthracen-2-yl)-2-hydroxy-2-methylpropyl 4-methylbenzenesulfonate 
• 1349697-69-3 (R)-1,5-bis(benzyloxy)-2-(2,3-dihydroxy-2-methylpropyl)anthracene-9,10-dione 
• 1349697-67-1 1,5-bis(benzyloxy)-2-(2-methylallyl)anthracene-9,10-dione 

Relevant academic research and scientific papers

De novo asymmetric synthesis of fridamycin e

A de novo asymmetric synthesis of (R)- and (S)-fridamycin E has been achieved. The entirely linear route required only nine steps from commercially available starting materials (16% overall yield). Key transformations included a Claisen rearrangement, a S